Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer.

MLA

Magalhães Filho, Marcos Aurélio Fonseca, et al. “Cost-Effectiveness Analysis of Ado-Trastuzumab Emtansine for the Treatment of Residual Invasive HER2-Positive Breast Cancer.” Einstein (Sao Paulo, Brazil), vol. 20, May 2022, p. eGS6655. EBSCOhost, https://doi.org/10.31744/einstein_journal/2022GS6655.

APA

Magalhães Filho, M. A. F., Aguiar, P. N., Jr, Neves, M. B. M., Lopes, G. de L., Jr, & Del Giglio, A. (2022). Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer. Einstein (Sao Paulo, Brazil), 20, eGS6655. https://doi.org/10.31744/einstein_journal/2022GS6655

Chicago

Magalhães Filho, Marcos Aurélio Fonseca, Pedro Nazareth Aguiar Jr, Milena Brachmans Mascarenhas Neves, Gilberto de Lima Lopes Jr, and Auro Del Giglio. 2022. “Cost-Effectiveness Analysis of Ado-Trastuzumab Emtansine for the Treatment of Residual Invasive HER2-Positive Breast Cancer.” Einstein (Sao Paulo, Brazil) 20 (May): eGS6655. doi:10.31744/einstein_journal/2022GS6655.